Steve Elms - 09 Feb 2026 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Reporting relationship: Director
Issuer ticker: ADMA
Reported as of: 09 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Feb 2026, 21:00:09 UTC
Prior SEC filing: 19 Nov 2025
Next SEC filing: 09 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Steve Elms, by Michael A. Goldstein as Attorney-in-fact

Key filing fact

Steve Elms filed Form 4 for ADMA BIOLOGICS, INC. (ADMA) on 11 Feb 2026.

Key facts

This page summarizes Steve Elms's Form 4 filing for ADMA BIOLOGICS, INC. (ADMA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 Feb 2026, 21:00.

Change

Previous filing in this sequence was filed on 19 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001250195 Primary reporting owner

ELMS STEVE

Relationship: Director
Address: C/O AISLING CAPITAL MANAGEMENT LP, 489 FIFTH AVENUE, 10TH FLOOR, NEW YORK
Signature: /s/ Steve Elms, by Michael A. Goldstein as Attorney-in-fact
Signature date: 11 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADMA transaction

Common Stock

Award

Transaction value: $0
Shares: +10,690
Change %: +12%
Price: $0.000000
Shares after: 98,020
Date: 09 Feb 2026
Ownership: Direct
Footnotes: F1, F2

ADMA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,031,730
Date: 09 Feb 2026
Ownership: See footnote
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADMA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +17,730
Change %
Price: $0.000000
Shares after: 17,730
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,730
Exercise price: $16.37
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.

Footnote F2

Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 81,885 shares of common stock owned by the Reporting Person.

Footnote F3

These shares are owned by Aisling Capital II LP ("Aisling"), which is a fund that was established in 2007 with a 10-year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Issuer and Aisling Partners' ownership of the Issuer's options, except to the extent of his pecuniary interest therein.

Footnote F4

These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.